What is the role of Iobenguane I 131 in the treatment of pheochromocytomas?

Updated: Aug 10, 2018
  • Author: Michael A Blake, MBBCh, MRCPI, FRCR; Chief Editor: George T Griffing, MD  more...
  • Print

Iobenguane I 131 was approved by the US Food and Drug Administration (FDA) in July 2018 for iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma in patients aged 12 years or older in whom systemic anticancer therapy is needed. The drug’s efficacy was demonstrated in a single-arm, open-label, phase-2 clinical trial performed under a special protocol assessment with the FDA. Seventeen (25%) of the study’s 68 evaluable patients were able to reduce all antihypertensive medication by 50% or more for at least 6 months; 15 patients (22%) obtained an overall tumor response. [67]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!